MESNA Injection for TMJ Internal Derangement

Treatment of Temporomandibular Joint Internal Derangement Using MESNA Injection

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05882604

Enrollment

Registered

2023-05-31

Start date

2023-03-01

Completion date

2024-03-10

Last updated

2025-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TMJ Disorder

Brief summary

The pathogenesis of temporomandibular disorders focusing on the biochemistry of the synovial fluid in various stages of temporomandibular joint disease. The role of inflammation has been investigated and proposed as an underlying mechanism of pain and dysfunction of temporomandibular joint. MESNA (sodium 2-mercaptoethanesulfonate) was approved several years ago and marketed in several formulations as a mucolytic agent in the respiratory field, since it breaks the disulfide bonds between polypeptide chains of mucus. The tissue distribution of MESNA is negligible, and the elimination of the substance is rapidly and completely achieved by kidney

Detailed description

Clarification (July 2025): Recruitment was completed in March 2023 following clinical scheduling and preliminary departmental clearance, while formal written ethical approval was finalized in early April 2023. All patients were followed up for one year, and the study was completed by March 2024.

Interventions

DRUGArthrocentesis with ringer solution

Two 20-gauge needles will be placed into upper joint space as entry and exit points for washing.The arthrocentesis will be performed with 100 ml of lactated Ringer's solution to eliminate the inflammatory mediators present in the synovial fluid

DRUGMesna Injection

1 ml of MESNA will be injected using 20-guage needle in he upper compartment of TMJ in patient with internal derrangement.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients with TMJ internal derangement with reduction

Exclusion criteria

* inflammatory or connective tissue disease * autoimmune disease history * neurologic problems

Design outcomes

Primary

Measure	Time frame	Description
maximal interincisal opening (MIO)	6 months	a digital caliper will be employed to measure the maximum interincisal opening pre and postoperative

Secondary

Measure	Time frame	Description
Joint pain	6 months	pain will be assessed on a visual analogue scale (VAS) with a score between 0 and 10, 0 means no pain and 10 means severe pain
clicking sound	6 months	yes or no questionnaire,yes mean clicking is present and no means clicking disappeared

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026